Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperlipoproteinemia Type II | 10 | 2020 | 347 | 2.290 |
Why?
|
| Blood Component Removal | 7 | 2020 | 114 | 2.010 |
Why?
|
| Lipoproteins, LDL | 3 | 2013 | 643 | 0.830 |
Why?
|
| Atherosclerosis | 12 | 2022 | 2958 | 0.760 |
Why?
|
| Carotid Artery Diseases | 7 | 2021 | 898 | 0.680 |
Why?
|
| Human Growth Hormone | 9 | 2013 | 662 | 0.670 |
Why?
|
| Colestipol | 1 | 2014 | 11 | 0.590 |
Why?
|
| Niacin | 1 | 2014 | 113 | 0.530 |
Why?
|
| Cholesterol, LDL | 9 | 2020 | 2228 | 0.530 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 545 | 0.530 |
Why?
|
| Lipoproteins | 4 | 2015 | 907 | 0.470 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 945 | 0.430 |
Why?
|
| Hyperlipoproteinemia Type I | 2 | 2019 | 10 | 0.390 |
Why?
|
| Anticholesteremic Agents | 2 | 2013 | 958 | 0.370 |
Why?
|
| Carotid Arteries | 8 | 2022 | 977 | 0.370 |
Why?
|
| HIV Infections | 14 | 2022 | 14979 | 0.340 |
Why?
|
| Tunica Media | 4 | 2011 | 127 | 0.340 |
Why?
|
| Oligonucleotides | 2 | 2019 | 605 | 0.290 |
Why?
|
| Tunica Intima | 4 | 2011 | 520 | 0.280 |
Why?
|
| Uganda | 8 | 2022 | 1055 | 0.280 |
Why?
|
| Triglycerides | 6 | 2020 | 2493 | 0.260 |
Why?
|
| Abdominal Fat | 3 | 2013 | 233 | 0.230 |
Why?
|
| HIV Seronegativity | 1 | 2021 | 204 | 0.210 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2022 | 330 | 0.210 |
Why?
|
| Heterozygote | 3 | 2019 | 2787 | 0.200 |
Why?
|
| Obesity, Abdominal | 2 | 2013 | 323 | 0.200 |
Why?
|
| Anti-HIV Agents | 4 | 2021 | 3955 | 0.190 |
Why?
|
| Growth Hormone-Releasing Hormone | 2 | 2012 | 210 | 0.190 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 327 | 0.190 |
Why?
|
| Acromegaly | 2 | 2012 | 325 | 0.180 |
Why?
|
| Urban Health | 1 | 2021 | 572 | 0.180 |
Why?
|
| Body Composition | 8 | 2013 | 2381 | 0.180 |
Why?
|
| Apolipoprotein C-III | 1 | 2019 | 198 | 0.180 |
Why?
|
| Cardiovascular Diseases | 13 | 2020 | 13413 | 0.170 |
Why?
|
| HIV Seropositivity | 1 | 2021 | 857 | 0.160 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 2062 | 0.160 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2021 | 1386 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 3016 | 0.150 |
Why?
|
| Homozygote | 1 | 2020 | 1855 | 0.140 |
Why?
|
| Fasting | 1 | 2020 | 1573 | 0.130 |
Why?
|
| Foundations | 1 | 2013 | 103 | 0.130 |
Why?
|
| Risk Factors | 22 | 2022 | 69278 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 2 | 2016 | 1513 | 0.120 |
Why?
|
| Rural Population | 2 | 2020 | 2103 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 1127 | 0.120 |
Why?
|
| Endothelium, Vascular | 2 | 2018 | 4686 | 0.110 |
Why?
|
| Antigens, CD | 3 | 2018 | 4256 | 0.110 |
Why?
|
| Middle Aged | 35 | 2022 | 216468 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 1712 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 1971 | 0.110 |
Why?
|
| HIV | 1 | 2018 | 1444 | 0.110 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 2944 | 0.100 |
Why?
|
| Phosphocreatine | 1 | 2010 | 284 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2013 | 2017 | 0.100 |
Why?
|
| Humans | 44 | 2022 | 686663 | 0.100 |
Why?
|
| Coronary Disease | 2 | 2016 | 6221 | 0.100 |
Why?
|
| Arteries | 1 | 2014 | 1088 | 0.100 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 21640 | 0.100 |
Why?
|
| Registries | 5 | 2019 | 8033 | 0.100 |
Why?
|
| Adult | 31 | 2022 | 211400 | 0.100 |
Why?
|
| Azetidines | 1 | 2010 | 153 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2020 | 60991 | 0.090 |
Why?
|
| Carotid Artery, Common | 2 | 2006 | 195 | 0.090 |
Why?
|
| Cholesterol, HDL | 4 | 2020 | 1768 | 0.090 |
Why?
|
| Arginine | 2 | 2010 | 943 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 575 | 0.090 |
Why?
|
| Fingers | 1 | 2011 | 512 | 0.090 |
Why?
|
| Receptors, LDL | 1 | 2010 | 539 | 0.080 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2008 | 136 | 0.080 |
Why?
|
| Obesity | 5 | 2012 | 11700 | 0.080 |
Why?
|
| Male | 31 | 2022 | 352465 | 0.080 |
Why?
|
| Female | 34 | 2022 | 375459 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 1917 | 0.080 |
Why?
|
| Growth Hormone | 1 | 2008 | 681 | 0.080 |
Why?
|
| Metformin | 1 | 2012 | 740 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2017 | 1714 | 0.070 |
Why?
|
| Radiography | 2 | 2014 | 7027 | 0.070 |
Why?
|
| Case-Control Studies | 6 | 2021 | 21684 | 0.070 |
Why?
|
| Botswana | 2 | 2018 | 942 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2010 | 723 | 0.070 |
Why?
|
| Pre-Eclampsia | 1 | 2011 | 985 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2019 | 13469 | 0.060 |
Why?
|
| Double-Blind Method | 6 | 2019 | 11866 | 0.060 |
Why?
|
| Adiponectin | 2 | 2008 | 1098 | 0.060 |
Why?
|
| Coronary Artery Disease | 2 | 2020 | 6030 | 0.060 |
Why?
|
| Lung | 1 | 2022 | 9182 | 0.060 |
Why?
|
| Risk Assessment | 6 | 2021 | 23739 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 833 | 0.060 |
Why?
|
| Adiposity | 1 | 2012 | 1656 | 0.060 |
Why?
|
| Ultrasonography | 5 | 2020 | 5876 | 0.060 |
Why?
|
| Smoking | 2 | 2022 | 9029 | 0.050 |
Why?
|
| Life Style | 1 | 2012 | 3604 | 0.050 |
Why?
|
| C-Reactive Protein | 5 | 2013 | 3569 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2018 | 1184 | 0.050 |
Why?
|
| Testosterone | 1 | 2010 | 2303 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 2592 | 0.050 |
Why?
|
| Spirometry | 1 | 2022 | 852 | 0.050 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 13444 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 8070 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 694 | 0.040 |
Why?
|
| Lipids | 4 | 2012 | 3131 | 0.040 |
Why?
|
| Mass Screening | 1 | 2013 | 5098 | 0.040 |
Why?
|
| Patient Selection | 1 | 2010 | 4381 | 0.040 |
Why?
|
| Pilot Projects | 3 | 2017 | 7791 | 0.040 |
Why?
|
| Aged | 11 | 2022 | 162271 | 0.040 |
Why?
|
| United States | 5 | 2017 | 65579 | 0.040 |
Why?
|
| Placebos | 2 | 2012 | 1791 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 1709 | 0.040 |
Why?
|
| Prevalence | 3 | 2021 | 14744 | 0.040 |
Why?
|
| Regression Analysis | 4 | 2013 | 6669 | 0.040 |
Why?
|
| Young Adult | 8 | 2019 | 56052 | 0.040 |
Why?
|
| Overweight | 1 | 2008 | 2139 | 0.040 |
Why?
|
| Platelet Count | 1 | 2019 | 793 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 3687 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2022 | 1739 | 0.040 |
Why?
|
| Cardiovascular System | 2 | 2013 | 744 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 12680 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2016 | 3226 | 0.040 |
Why?
|
| E-Selectin | 1 | 2018 | 583 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 727 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2022 | 38732 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2021 | 49071 | 0.040 |
Why?
|
| Biostatistics | 1 | 2016 | 162 | 0.040 |
Why?
|
| Inflammation | 1 | 2014 | 9617 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2019 | 6685 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2017 | 648 | 0.030 |
Why?
|
| Lovastatin | 1 | 1994 | 119 | 0.030 |
Why?
|
| Time Factors | 4 | 2021 | 42271 | 0.030 |
Why?
|
| Aging | 1 | 2013 | 8222 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 1141 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2017 | 10108 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 1480 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 128 | 0.030 |
Why?
|
| American Heart Association | 1 | 2017 | 933 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 15407 | 0.030 |
Why?
|
| Asian Americans | 1 | 2017 | 698 | 0.030 |
Why?
|
| Cholesterol | 2 | 2006 | 2751 | 0.030 |
Why?
|
| Adrenal Insufficiency | 1 | 2012 | 165 | 0.030 |
Why?
|
| Cellulose | 1 | 2011 | 138 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 2011 | 246 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 1186 | 0.030 |
Why?
|
| Sex Factors | 2 | 2017 | 10926 | 0.030 |
Why?
|
| Hyperemia | 1 | 2011 | 227 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 336 | 0.030 |
Why?
|
| Mitochondria, Muscle | 1 | 2010 | 176 | 0.020 |
Why?
|
| Solubility | 1 | 2011 | 1192 | 0.020 |
Why?
|
| Viral Load | 1 | 2018 | 3216 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 427 | 0.020 |
Why?
|
| Phenotype | 2 | 2017 | 16091 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2018 | 3105 | 0.020 |
Why?
|
| Cardiology | 1 | 2019 | 1625 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 572 | 0.020 |
Why?
|
| Intra-Abdominal Fat | 1 | 2012 | 558 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12734 | 0.020 |
Why?
|
| Monocytes | 1 | 2017 | 2643 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 346 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 1983 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2012 | 6125 | 0.020 |
Why?
|
| Body Mass Index | 3 | 2009 | 12323 | 0.020 |
Why?
|
| Boston | 2 | 2011 | 9534 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2361 | 0.020 |
Why?
|
| Anthropometry | 1 | 2009 | 1456 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 13204 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 4184 | 0.020 |
Why?
|
| Adolescent | 4 | 2012 | 84957 | 0.020 |
Why?
|
| Exercise Test | 1 | 2010 | 2129 | 0.020 |
Why?
|
| Hormones | 1 | 2006 | 777 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1994 | 4461 | 0.010 |
Why?
|
| Body Size | 1 | 2005 | 475 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 2972 | 0.010 |
Why?
|
| African Americans | 1 | 2017 | 5144 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2020 | 67320 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10648 | 0.010 |
Why?
|
| Internet | 1 | 2013 | 3097 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 7865 | 0.010 |
Why?
|
| Cytokines | 1 | 2015 | 7147 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13807 | 0.010 |
Why?
|
| Mitochondria | 1 | 2013 | 3602 | 0.010 |
Why?
|
| Massachusetts | 1 | 2013 | 8920 | 0.010 |
Why?
|
| Physicians | 1 | 2016 | 4060 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 4958 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 1604 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2009 | 2445 | 0.010 |
Why?
|
| Quality of Life | 2 | 2010 | 10676 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 4076 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 5981 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 7060 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 7631 | 0.010 |
Why?
|
| Risk | 1 | 2010 | 9915 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2013 | 3836 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 5134 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39737 | 0.010 |
Why?
|
| Hypertension | 1 | 2016 | 7941 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2006 | 4256 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 4960 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3808 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 17071 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2006 | 3232 | 0.010 |
Why?
|
| Insulin | 1 | 2008 | 6521 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 59331 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2008 | 8529 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 20409 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 25703 | 0.010 |
Why?
|
Concepts
(203)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(42)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_